and recommendation
Cytori Therapeutics, Inc. (CYTX)
Cytori Therapeutics, Inc. develops cellular therapeutics for specific diseases and medical conditions.
CYTX primarily provides Cytori Cell Therapy, which is in Phase III pivotal clinical trial for the treatment of impaired hand function in scleroderma.
CYTX offers Celution System devices, proprietary enzymes, and sterile consumable sets that are used at the point-of-therapeutic application or at an off-site processing center; and StemSource cell and tissue banking systems, as well as surgical accessories and instruments.
CYTX also provides ATI-0918, a liposomal encapsulation of doxorubicin for use in treating breast cancer, ovarian cancer, multiple myeloma, and Kaposi's sarcoma; and ATI-1123, a liposomal formulation of docetaxel for the treatment of non-small cell lung cancer, breast cancer, squamous cell carcinoma of the head and neck cancer, gastric adenocarcinoma, and hormone refractory prostate cancer.
The company was founded in 1996 and is headquartered in San Diego, California.
- November 7, 2014 - 11:17am | Earnings
- October 31, 2014 - 9:49am | Out and About
- October 22, 2014 - 7:19pm | Regulatory
- October 21, 2014 - 10:09am | IP & Patents
- October 21, 2014 - 8:55am | BOD & C-Suite Updates
- October 16, 2014 - 2:13pm | Earnings Q3
- October 8, 2014 - 8:18am | Financings
- September 30, 2014 - 12:49pm | Financings
- September 22, 2014 - 11:14am | Research Notes
- September 21, 2014 - 9:22am | Research Notes
- September 9, 2014 - 7:56am | Financings
- September 8, 2014 - 3:18pm | Model Portfolio
- September 2, 2014 - 8:11am | Out and About
- August 19, 2014 - 8:18am | Research Notes
- August 18, 2014 - 2:31pm | BOD & C-Suite Updates
- August 18, 2014 - 1:39pm | Earnings
- August 12, 2014 - 12:56pm | Research Notes
- August 12, 2014 - 9:57am | BOD & C-Suite Updates
- August 10, 2014 - 12:56pm | Clear and Present Dangers
- August 5, 2014 - 6:28pm | Research Notes